Skip to main content
Signal8
Launch Terminal

Apnimed, Inc. (APMD)

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Apnimed, Inc. logo

Apnimed, Inc.

NASDAQ:APMDHealthcare
-5.42%$16.40
AH$16.97+3.48%vs close
Mkt Cap$682.74M
Float17.93M
O/S41.63M
Vol
$ Vol
RVOL
Inst Own0.0%
SI10.1%
Earnings
Dilution
Apnimed, Inc. logoNASDAQ:APMD$16.40-5.42%
FormDescription
S-8
SEC Filing
10-Q
Quarterly Report
8-K
2.02,9.01
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
5.03,9.01
S-8
SEC Filing
424B4
Prospectus
EFFECT
Notice of Effectiveness
3
Initial Statement of Beneficial Ownership
S-1MEF
SEC Filing
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership

1-25 of 54

    Apnimed, Inc. (APMD) SEC Filings: 10-K, 10-Q, 8-K, Form 4 | Signal8